Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6

What Was Tested

This randomized controlled trial paper looks at Semaglutide in the context of low blood pressure and orthostatic hypotension.

This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and high cardiovascular risk.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

What Was Measured

PubMed files the paper under topics including Albuminuria, Blood Pressure, Body Mass Index, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucagon-Like Peptides and Glycated Hemoglobin.

Author keywords: cardiovascular risk, eGFR decline and semaglutide.

What This Means in Plain Language

The paper is a randomized and double-blind study of Semaglutide in people with low blood pressure and orthostatic hypotension.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Semaglutide compound page, Low blood pressure and orthostatic hypotension research.